Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co LtdfiledCriticalSanten Pharmaceutical Co Ltd
Priority to JP54105414ApriorityCriticalpatent/JPS5934185B2/en
Publication of JPS5555165ApublicationCriticalpatent/JPS5555165A/en
Publication of JPS5934185B2publicationCriticalpatent/JPS5934185B2/en
NEW MATERIAL:N-(Benzoylmercapto substituted acyl)-histidine of formula V: (n is 1 or 2).
USE: Drugs for arteriosclerosis or an intermediate for the novel compound of formula I which is one of the drugs.
PROCESS: A halogen substituted acyl halogenide of formula II is reacted with histidine of formula III by the Schotten-Baumann method to give an N-(halogen substituted acyl)-histidine of formula IV which is reacted with an alkali thiobenzoate or its aqueous solution to form the desired compound of formula V. The resulting compound is treated with an aqueous ammonia to afford the compound of formula I. Histidine of formula III may be any one of optically active isomers or racemic modifications.